Skip to main content
Top

The Expanding Role of Continuous Glucose Monitoring in the Management and Prevention of Type 2 Diabetes

Abstract

Continuous glucose monitoring (CGM) has transformed diabetes management by providing continuous, high-resolution insight into glucose dynamics. Initially developed for type 1 diabetes, CGM now demonstrates substantial clinical and behavioral benefits for individuals with type 2 diabetes across diverse therapeutic settings. This narrative review synthesizes current evidence on the expanding role of CGM in optimizing glycemic control and promoting patient-driven lifestyle modification.
Across randomized and real-world studies, CGM consistently improves glycosylated hemoglobin, increases time in range, and reduces glycemic variability, regardless of insulin use. Beyond metabolic outcomes, CGM enhances treatment satisfaction, psychological well-being, and self-efficacy, particularly when combined with structured education and feedback. By enabling individuals to visualize real-time glucose responses to daily behaviors, CGM serves as a powerful catalyst for sustained behavioral change and personalized self-management.
In addition to its therapeutic applications, CGM also provides diagnostic insight by revealing unrecognized glucose excursions that conventional monitoring may miss, facilitating earlier identification of dysglycemia in at-risk individuals. Yet significant barriers persist, including device costs, limited insurance coverage, and the difficulty of translating raw data into actionable insights for patients and clinicians.
In conclusion, CGM has evolved from a glucose-monitoring device to a comprehensive platform that supports both clinical decision-making and behavioral empowerment, bridging the continuum from diabetes prevention to long-term management.
Title
The Expanding Role of Continuous Glucose Monitoring in the Management and Prevention of Type 2 Diabetes
Authors
Heejun Son
Sun-Joon Moon
Young Min Cho
Publication date
19-12-2025
Publisher
Springer Healthcare
Published in
Diabetes Therapy
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI
https://doi.org/10.1007/s13300-025-01830-8
This content is only visible if you are logged in and have the appropriate permissions.

Raising the standard: ensuring patient safety through minimum requirements for CGM performance

Prof. Chantal Mathieu highlights how the absence of rigorous performance standards for continuous glucose monitors in Europe contributes to wide variability in device accuracy, raising important concerns about patient safety.

Supported by:
  • Abbott Diabetes Care
Prof. Chantal Mathieu
Watch now
Video

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more
Image Credits
Woman checking CGM readings on a smartphone/© Javier Zayas Photography / Moment / Getty Images (symbolic image with model), Woman monitoring glucose level with sensor and an app on her phone while training at swimming pool/© (M) Goffkein, stock.adobe.com (symbolic image with model), Person walking/© _KUBE_ / Stock.adobe.com